Skip to main content

Getting Closer, But Work Remains

Premium

While progress is being made toward the goal of personalized medicine for cancer patients, much work remains, writes Rachael Rettner at MyHealthNewsDaily. "We're much better than we were a decade ago" at tailoring patients' treatments, Monter Cancer Center's Daniel Budman tells Rettner. Much of this progress is being fueled by advances in genome sequencing — which is falling quickly in price — as sequencing can be used to find the mutations in a particular patient's tumor. Marc Symons from the Feinstein Institute for Medical Research adds that the main hurdle is determining which mutations affect the course of the disease and finding drugs that target those mutations.

The Scan

WHO OKs Emergency Use of Sinopharm Vaccine

The World Health Organization has granted emergency approval for Sinopharm's SARS-CoV-2 vaccine, the Guardian reports.

Scientific Integrity Panel to Meet

According to the Associated Press, a new US scientific integrity panel is to meet later this week.

Trying in the Eye

NPR reports that a study of Editas Medicine's CRISPR therapy for Leber congenital amaurosis has begun.

PLOS Papers on Cerebellum Epigenetics, Copy Number Signature Tool, Acute Lung Injury Networks

In PLOS this week: epigenetics analysis of brain tissue, bioinformatics tool to find copy number signatures in cancer, and more.